Western blot analysis of extracts from HEL 92.1.7 cells, untreated (-) or treated with Ruxolitinib (300 nM, 24h; +), using Phospho-Stat3 (Tyr705) (D3A7) XP® Rabbit mAb #9145 (upper), Stat3 (D1B2J) Rabbit mAb #30835 (middle), or β-Actin (D6A8) Rabbit mAb #8457 (lower).
Chemical structure of Ruxolitinib.
Ruxolitinib is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.09 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Molecular Weight: 306.4 g/mol
Molecular Formula: C17H18N6
Solubility: Soluble in DMSO at 28 mg/ml or ethanol at 15 mg/ml with slight warming.
Ruxolitinib, also known as INCB018424, is a potent and selective ATP-competitive inhibitor of Jak1, Jak2, and Jak3 with an IC50 value of 2.7, 4.5, and 322 nM, respectively (1,2). This small molecule can block IL-6 signaling (IC50 = 281 nM) and proliferation of Jak2V617F+ Ba/F3 cells (IC50 = 127 nM) (3). The effect that Ruxolitinib has on Jak-signaling leads to the decreased circulation of the proinflammatory cytokines IL-6 and TNF-α, making it an important compound when studying myeloproliferative neoplasms (MPNs) (3).
This product has applications to SARS-CoV-2 research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.